Navlimetostat Wet vs Dry Granulation Tablet PK Study
Summary
A new Phase 1 clinical trial (NCT07544628) has been registered on ClinicalTrials.gov to compare the pharmacokinetics of Navlimetostat administered as a wet-granulation tablet versus a dry-granulation tablet formulation in healthy adult female participants. The study, registered by NIH, documents an early-stage bioequivalence investigation of two tablet manufacturing approaches for the drug candidate.
“This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A Phase 1 clinical trial (NCT07544628) has been registered on ClinicalTrials.gov evaluating the pharmacokinetics of Navlimetostat administered as a wet-granulation tablet versus a dry-granulation tablet formulation. The study enrolls healthy adult female participants and is registered with an April 22, 2026 effective date.\n\nThis registry entry is informational and creates no regulatory obligations. Sponsors and clinical investigators monitoring competitive or同类药物 development may use this entry to track early-phase bioequivalence studies for Navlimetostat.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase 1 Study of Navlimetostat Tablet Formulations
Phase 1 NCT07544628 Kind: PHASE1 Apr 22, 2026
Abstract
This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female
Conditions: Healthy Participants
Interventions: Navlimetostat
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.